DALLAS, TX / ACCESSWIRE / March 27, 2020 / CerSci Therapeutics (“CerSci”), a non-opioid pain relief drug development company based in Dallas, Texas today announced that Dr. Lucas Rodriguez, Chief Executive Officer plans to present an overview of the company and provide a business update at the upcoming Solebury Trout Virtual Global Healthcare Conference Series. During the 25 minute presentation, participants will be able to submit questions electronically. Details are as follows:
Date/Time: Tuesday, March 31, 2020 at 1:30 p.m. EDT
To access the presentation, please login HERE
Webcast archive: 24 hours following the presentation an archive of the event will be available on the Company’s website at www.cersci.com
About CerSci Therapeutics
CerSci is a clinical-stage pharmaceutical company developing non-opioid analgesic drug products without the deleterious side effects (e.g., abuse liability, cognitive impairment, respiratory depression, etc.) of current pain treatments on the market. CerSci’s lead candidate, CT-044, is a novel, orally bioavailable compound that will initially target post-operative and chronic neuropathic pain indications.
Investor Relations Contact:
Chiara Russo
Solebury Trout
+617-221-9197
crusso@soleburytrout.com
SOURCE: CerSci Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/582880/CerSci-Therapeutics-to-Present-at-the-Upcoming-2020-Solebury-Trout-Virtual-Global-Healthcare-Conference-Series
MIAMI, FLORIDA / ACCESS Newswire / December 7, 2025 / MSP Recovery, Inc. (NASDAQ:MSPR) (the…
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…